Purpose. Pathologic stage II melanoma patients have variable outcomes when divided by substage. We hypothesized that an understanding of the patterns of initial relapse by substage will better inform follow-up guidelines. Methods. We performed a retrospective review of 738 adult patients with pathologic stage II cutaneous melanoma treated at Memorial Sloan Kettering Cancer Center between 1993 and 2013. Clinical records were reviewed to determine time, location, and method of detection of initial relapse. Results. At a median follow-up of 52 months, 219 patients relapsed. Relapses were detected more frequently in higher substages. Initial relapses were most commonly local/intransit for IIA and IIB and systemic for IIC. Lung and brain were the most frequent sites of systemic relapse. Patientdetection was the most common method of relapse detection (59%) in all substages. The 5-year cumulative incidence for patient-detected relapse was 13.6% for IIA, 18.9% for IIB, and 23.3% for IIC and for image-detected relapse was 3.4, 7.9, and 16.6%, respectively. The 5-year cumulative incidence for physician-detected relapse was less than 10% across all substages and leveled off at 3 years for stage IIA and IIB and 2 years for stage IIC. Conclusions. Relapses were most frequently patient-detected in all stage II substages, highlighting the importance of patient education and self-examination. The highest yield for routine imaging is in stage IIC patients during the first 4 years. Physician examination is unlikely to detect relapses beyond 3 years for stage IIA and IIB and beyond 2 years for stage IIC patients.
Pathologic stage II melanoma patients are a group of patients that have, by definition, undergone nodal staging by sentinel lymph node biopsy or elective lymph node dissection and been found to be node negative. Stage IIA includes melanomas 1.01-2.00-mm thick with ulceration or 2.01-4.00-mm thick without ulceration. Stage IIB includes melanomas 2.01-4.00-mm thick with ulceration or [4.00-mm thick without ulceration. Stage IIC includes only melanomas [4.00-mm thick with ulceration. 1 Survival for pathologic stage II melanoma patients varies greatly by AJCC substage, making it difficult to define the optimal surveillance schedule for resected pathologic stage II patients. Five-year survival ranges from 80% for stage IIA to 53% for IIC 1 . In 2010, Romano et al. described the site and timing of relapse for pathologic stage III melanoma patients, creating the opportunity to establish evidence-based follow-up guidelines that are substagespecific. 2 This study was designed to analyze pathologic stage II melanoma patients by (1) characterizing the site and timing of initial relapse by substage; (2) analyzing the methods of detection for substage-specific initial relapse; (3) recommending evidence-based follow-up guidelines by substage.
PATIENTS AND METHODS
From a prospectively maintained, single-institution database, we identified 738 adult patients with resected pathologic AJCC (7th edn.) stage II primary cutaneous melanoma treated at Memorial Sloan Kettering Cancer Center (MSKCC) between January 1993 and December 2013. 1 All patients underwent pathologic nodal staging by sentinel lymph node biopsy (n = 735) or elective lymph node dissection (n = 3). From our database and electronic medical record, we extracted demographic information, primary melanoma characteristics, current disease and survival status, and initial relapse descriptors including site, time from initial resection, and method of detection.
Standard follow-up included evaluation by a surgical oncologist, medical oncologist, or dermatologist every 3-6 months for the first 2 years and then every 6-12 months thereafter. Serum laboratory values were rarely used for surveillance. CT scans and chest X-rays were performed in asymptomatic patients at the treating physician's discretion.
Synchronous initial relapses were scored by the most advanced site (systemic sites outranked nodal sites, which outranked local/in-transit). Second primary melanomas were not recorded as relapses. Appropriate symptoms reported at the same time as a corresponding image-detected relapse were recorded as patient-detected.
Access to patient information was approved by the MSKCC Institutional Review Board.
Statistical Analysis
Disease-specific survival (DSS) and time to relapse (TTR) were calculated from the time of operation. Curves were generated using the Kaplan-Meier product-limit method. Patients were censored at the time of non-melanoma death or last follow-up for DSS and at the time of death without relapse or last follow-up for TTR. Cumulative incidence functions were used to estimate the incidence of recurrence by method of detection, using death without recurrence as a competing event. Five-year cumulative incidence and 95% confidence intervals are reported by method of detection and substage.
RESULTS

Clinicopathologic Characteristics and Outcomes
We identified 738 patients with pathologic stage II cutaneous melanoma: 400 stage IIA, 226 stage IIB, and 112 stage IIC patients (Table 1) . Median age was 62 years. The most common primary site was the extremity (45%), followed by trunk (36%), and head and neck (19% Fig. 1 ).
Patterns of Initial Relapse by Substage
Relapses were divided into three sites (local/in-transit, nodal, and systemic) and were analyzed by substage (Fig. 1a-c) . Among the observed relapses, initial relapses were most frequently local/in-transit in stage IIA (41%) and IIB (47%), whereas IIC relapses were most frequently systemic (52%).
Systemic relapses were detected in 32 stage IIA patients, 22 stage IIB patients, and 27 stage IIC patients (Fig. 1d) . Lung was the most frequent site of systemic relapse in all substages (n = 11, 11, and 13 for stage IIA, IIB, and IIC, respectively). The second most frequent site was brain for IIA (n = 9) and IIC (n = 5), and liver for IIB (n = 4). Three IIA patients had a rare site of distant metastasistwo to the larynx, and one to the heart. Of detected relapses, 187 occurred within the first 5 years (Supplemental Table 1 ). Of the 32 relapses detected after 5 years, 21 were initially stage IIA, 6 were IIB, and 5 were IIC. Fourteen were systemic, 10 were nodal, and 8 were local/in-transit relapses.
Method of Detection of Initial Relapse
We were able to determine the method of detection for 211 initial relapses, which were divided into three categories: (1) patient-detected, (2) physician-detected, and (3) image-detected. We excluded one patient whose elevated LDH served as the method of detection, leaving 210 patients for final analysis (Fig. 2) . Patient-detection was the most frequent method across all sites and substages. Patients were able to identify 62% of local/in-transit, 69% of nodal, and 50% of systemic relapses by detection of a visible/palpable lesion or by reporting symptoms that prompted further evaluation. By substage, patient-detection 
Cumulative Relapse Incidence by Method of Detection
Patient-detected relapses not only had the highest 5-year cumulative incidence in all substages (Fig. 3d) but also was the only method that did not reach a plateau by 5 years (Fig. 3a-c) . In contrast, the cumulative incidence of physician-detected relapses levels off by 3 years for stage IIA and IIB and by 2 years for IIC. The 5-year cumulative incidence of physician-detected relapses was \10% in all substages. The 5-year cumulative incidence of image-detected relapses was higher for stage IIC (16.6%) than IIB (7.9%) and IIA (3.4%), consistent with higher rates of stage IIC systemic relapses. There was only one image-detected relapse after 5 years.
DISCUSSION
Current NCCN guidelines divide primary melanoma patients into two follow-up groups: stage IA-IIA and stage IIB-IV. 3 The latter represents a broad range of relapse risks. Combined with the lack of actionable prospective studies on optimal follow-up strategies, this has led to guidelines that allow variable visit intervals and a wide range of acceptable imaging strategies. International melanoma guidelines suffer from a similar lack of data. A 2012 systematic review of stage-specific surveillance practices found wide variability in visit frequency and use of surveillance imaging and blood tests across countries with consensus guidelines. 4 Two prospective studies have examined melanoma follow-up schedules. Garbe et al. followed 2008 consecutive stage I-IV cutaneous melanoma patients with physical examinations every three months and routine nodal basin ultrasounds. In their stage I/II cohort, early relapse detection was associated with improved 3-year overall survival (76 vs. 38%). 5 However, it is unclear how much of the survival advantage was attributable to lead-time bias versus earlier treatment opportunities. In a German multicenter, 4-year prospective study, Livingstone et al. found that only 7.7% of stage I-III patients (n = 555) developed first or additional metastases after 3 years. 6 They recommended reduced follow-up for low-risk patients but were unable to draw conclusions for the stage II cohort, who represented only 13% of their study population. The Melanoma Follow-up (MELFO) trial in the Netherlands has accrued 180 stage IB/II patients and prospectively randomized them to either a conventional follow-up schedule (4 visits yearly) or a less frequent ''experimental'' schedule. Preliminary results after 1 year showed no difference in recurrence and self-detection rates, no adverse effect on mental well-being, and a 45% reduction in follow-up cost. 7 We present the largest series dedicated to outcomes of pathologic stage II melanoma patients. Our first goal was to characterize the site and timing of initial relapse by substage. Our data confirm that increasing substage is associated with progressively worse rates of relapse and melanoma-specific survival. Stage IIC patients relapsed more frequently, earlier, and were more likely to relapse systemically. Lung was the most common site of metastasis, followed by brain. Low rates of other site-specific systemic relapse suggest that routine imaging targeted at other sites or in stage IIA patients is of exceedingly low yield.
Our second goal was to analyze the method of detection of initial relapse by substage. Shumate et al. found that symptoms were present in 90% of patients with recurrent melanoma and accurately predicted the site of recurrence. 8 Furthermore, overall survival was not affected by whether the recurrence was detected during a routine versus unscheduled visit. Additional studies have confirmed that most relapses are patient-detected and demonstrated no survival difference between symptomatic and asymptomatic patients.
2,9-13 In our cohort, relapses were most frequently patient-detected in all substages, and the cumulative incidence of patient-detected relapse continues to increase the past 5 years. The cumulative incidence of physician-detected relapses plateaus around 3 years for IIA and IIB and by 2 years for IIC, providing a natural time point for patients to transition to annual or as-needed follow-up. Image-detected relapses plateau at 3 years for IIB and 4 years for IIC. The cumulative incidence of death without recurrence continues to rise in all substages, implying that while the decrease in relapse incidence is in part due to less intensive follow-up, it also is due to ongoing all-cause mortality.
Our final goal was to propose substage-specific guidelines for the frequency and duration of physician visits and routine imaging based on the above results (Supplemental Table 2 ). We recommend routine visits for 3 years for stage IIA and IIB, with less frequency for IIA. For stage IIC, we recommend routine visits for the first 4 years, with the latter 2 years primarily to assist in imaging interpretation. We recommend against routine imaging for stage IIA but would consider annual surveillance imaging for 3 years for IIB and every 6-12 months for 4 years for IIC. for relapse and death without relapse. Relapses are broken down by method of detection and substage imaging for IIC. Once on annual visits and not undergoing surveillance imaging, we recommend transition into a survivorship program. This has the added benefits of ongoing education on prevention and self-examination and identifying and managing treatment complications and toxicities, while facilitating systematic data recording for future studies. This is not, however, to diminish the importance of routine dermatologic surveillance, because melanoma patients have a ninefold increased risk of a second invasive primary melanoma and a fourfold increased risk of a nonmelanoma skin cancer.
14,15 These recommendations intentionally leave flexibility for individual tailoring based on additional patient risk factors, such as age, sex, and tumor location. [16] [17] [18] [19] It should be emphasized that these are only guidelines, and clinical judgement must be used to adapt them to an individual patient based on the previously mentioned risk factors, as well as patient anxiety level, personal history of melanoma, and availability of resources. Results of the MELFO trial will further guide follow-up for stage II patients; however, prospective, randomized trials of multiple follow-up strategies will be exceedingly difficult due to the number of patients required.
In a single-center cost evaluation, Hofmann et al. found that routine imaging in stage I/II patients (n = 554) detected only 21% of initial relapses but accounted for almost half the cost. 13 In this study, routine imaging included nodal basin ultrasound and chest x-ray but not PET/CT, brain MRI, or chest CT. Use of the latter would likely increase costs with little additional yield. Rueth et al. did a comparative analysis of stage-specific surveillance strategies and found in pathologic stage II melanoma patients, the positive predictive value was 12.7% for annual PET/CT and 4.5% for annual CT. 20 These are low in part due to a higher false-positive rate, which invariably adds cost by stimulating additional testing. The expected average life expectancy increase with image-detected relapse treatment was only 1 month. This study divided patients by stage III substage but was unable to do so for the smaller stage II cohort (n = 72). A German cost analysis for stage II melanoma patients demonstrated the median cost to detect a recurrence with clinical examination was €2,715 ($3,910US) versus €32,007 ($46,090US) when using surveillance imaging. 21 Although our study does not directly address the cost-effectiveness of various follow-up strategies, our data suggest that we can implement a more efficient, cost-effective follow-up strategy by decreasing use of routine imaging in low-risk patients, increasing patient education on symptom identification and self-examination, and decreasing the frequency of physician visits.
Although these data were obtained from a prospectively maintained database, it is still susceptible to the usual limitations of a retrospective study. We do not have full data in regards to the frequency and type of surveillance imaging performed that did not detect any relapses. This is not a prospectively collected data point in our database, and because care of our patients often is shared with their local physicians, we would not be able to retrieve accurately this information retrospectively. This limits our ability to draw conclusions on the type of surveillance imaging with highest yield and the optimal frequency for imaging. However, the data regarding where and when patients relapse can help guide physicians in planning their follow-up strategies.
Our median follow-up is just short of 5 years. While this may underestimate the true long-term risk of relapse, previous studies also have shown that a majority of relapses occur within the first 5 years. 12, 22, 23 Our study is naturally biased towards patient-detection in the later years, when physician visits and imaging are performed less frequently. One could argue that some of these patient-detected relapses could have been detected earlier had imaging been performed. However, even if imaging could have led to earlier detection of all late ([5 year) patient-detected relapses, this would have only affected 14 stage IIA, 2 IIB, and 5 IIC patients. It would be difficult to justify continued radiographic surveillance of the entire group for such a low yield, especially given the lack of evidence that earlier image-detection affects overall survival.
In the new era of systemic treatment for unresectable or metastatic melanoma, immunotherapy and targeted therapies have shown improved rates of objective response, prolonged duration of response, and a favorable overall survival rate compared with traditional chemotherapy. [24] [25] [26] [27] [28] Naturally, these new therapies are being tested in the adjuvant setting. However, it has yet to be shown that survival is improved with earlier detection and treatment using these newer agents in the minimal residual disease setting. The current adjuvant trials with these highly active therapies compare adjuvant therapy versus no adjuvant therapy, but the real question will be whether adjuvant therapy for all patients after surgery (i.e., treatment now) is better than treating only relapsed patients at the time of relapse (i.e., treatment later if needed). As we gain more long-term experience with these treatments, we anticipate that the national guidelines will be revisited and updated to reflect the most current data.
CONCLUSIONS
Rates of melanoma have been increasing approximately 3% per year despite stable mortality rates, which cannot be explained entirely by increases in thin melanomas secondary to screening. 29 With increasing numbers of melanoma survivors, there is an increased burden on the system for surveillance. This study found low rates of image-detected relapse in stage IIA, supporting current NCCN recommendation against routine imaging for stage IIA. The kinetics of initial relapse reveal that a majority of physician-detect relapses occur within 3 years for stage IIA/IIB and 2 years for IIC, allowing for earlier transition to annual visits with a survivorship focus than currently recommended. We verified that stage IIC represents a distinct higher risk group that deserves close follow-up in the early years when overall and systemic relapse rates are highest. Early relapse detection must be balanced against surveillance costs. Based on these data, we suggest that changes in follow-up guidelines must be substage-specific and account for the yield of physician follow-up and imaging.
